{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,2]],"date-time":"2026-03-02T18:59:21Z","timestamp":1772477961123,"version":"3.50.1"},"reference-count":165,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,3,2]],"date-time":"2026-03-02T00:00:00Z","timestamp":1772409600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,3,2]],"date-time":"2026-03-02T00:00:00Z","timestamp":1772409600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cancer Metastasis Rev"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\n                    CAR-T cell therapy, which uses endogenous T cells engineered to target specific cancer antigens, is one of the most promising recent developments in the treatment of hematologic malignancies in both children and adults. CAR-T cells have shown tremendous success in treating B-cell lymphoma, acute lymphoblastic leukemia, and multiple myeloma, and they are currently FDA-approved for the treatment of six hematologic malignancies. Its success in solid tumors has been more modest, which has been attributed to several factors including the hostile tumor microenvironment (TME), poor persistence of CAR-T cells, and difficulty directing CAR-T cells towards solid tumors. Armored CAR-T cells, which modify the TME via secreted cytokines, have shown early success in the treatment of solid pediatric malignancies. We review recent trials of CAR-T cells to treat common pediatric solid malignancies, including Ewing sarcoma, osteosarcoma, neuroblastoma, diffuse intrinsic pontine glioma, rhabdomyosarcoma, Wilms tumor, and retinoblastoma. We focused particularly on armored CAR-T cells where applicable. Armored CAR-T cells have been utilized to target a variety of tumor-associated antigens on pediatric solid tumors with early successes both\n                    <jats:italic>in vivo<\/jats:italic>\n                    and\n                    <jats:italic>in vitro<\/jats:italic>\n                    , and innovative approaches for addressing their limitations are rapidly being developed.\n                  <\/jats:p>","DOI":"10.1007\/s10555-026-10317-2","type":"journal-article","created":{"date-parts":[[2026,3,2]],"date-time":"2026-03-02T05:33:16Z","timestamp":1772429596000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["CAR-T cell therapy for pediatric solid tumors: armored CAR-T cells and beyond"],"prefix":"10.1007","volume":"45","author":[{"ORCID":"https:\/\/orcid.org\/0009-0005-8272-5092","authenticated-orcid":false,"given":"Jeremy","family":"Wells","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6074-9847","authenticated-orcid":false,"given":"Ajay","family":"Gupta","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2026,3,2]]},"reference":[{"key":"10317_CR1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ebiom.2020.102931","author":"J Jayaraman","year":"2020","unstructured":"Jayaraman, J., et al. (2020). CAR-T design: Elements and their synergistic function. EBioMedicine. https:\/\/doi.org\/10.1016\/j.ebiom.2020.102931","journal-title":"EBioMedicine"},{"issue":"6382","key":"10317_CR2","doi-asserted-by":"publisher","first-page":"1361","DOI":"10.1126\/science.aar6711","volume":"359","author":"CH June","year":"2018","unstructured":"June, C. H., et al. (2018). CAR T cell immunotherapy for human cancer. Science, 359(6382), 1361\u20131365.","journal-title":"Science"},{"key":"10317_CR3","first-page":"20","volume":"13","author":"XM Zhang","year":"2022","unstructured":"Zhang, X. M., et al. (2022). CAR-T cell therapy in hematological malignancies: Current opportunities and challenges. Frontiers in Immunology, 13, 20.","journal-title":"Frontiers in Immunology"},{"issue":"6","key":"10317_CR4","doi-asserted-by":"publisher","first-page":"19","DOI":"10.3390\/jcm12062326","volume":"12","author":"M Kulczycka","year":"2023","unstructured":"Kulczycka, M., et al. (2023). CAR T-cell therapy in children with solid tumors. Journal of Clinical Medicine, 12(6), 19.","journal-title":"Journal of Clinical Medicine"},{"issue":"22","key":"10317_CR5","doi-asserted-by":"publisher","first-page":"1924","DOI":"10.1001\/jama.2024.19462","volume":"332","author":"JN Brudno","year":"2024","unstructured":"Brudno, J. N., Maus, M. V., & Hinrichs, C. S. (2024). CAR T cells and T-cell therapies for cancer: A translational science review. JAMA, 332(22), 1924\u20131935.","journal-title":"JAMA"},{"issue":"1","key":"10317_CR6","doi-asserted-by":"publisher","first-page":"126","DOI":"10.1186\/s12943-025-02334-6","volume":"24","author":"Y Lu","year":"2025","unstructured":"Lu, Y., & Zhao, F. (2025). Strategies to overcome tumour relapse caused by antigen escape after CAR T therapy. Molecular Cancer, 24(1), 126.","journal-title":"Molecular Cancer"},{"issue":"1","key":"10317_CR7","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1186\/s12935-024-03315-3","volume":"24","author":"T Chen","year":"2024","unstructured":"Chen, T., et al. (2024). Current challenges and therapeutic advances of CAR-T cell therapy for solid tumors. Cancer Cell International, 24(1), 133.","journal-title":"Cancer Cell International"},{"key":"10317_CR8","first-page":"95","volume":"15","author":"ER Hawkins","year":"2021","unstructured":"Hawkins, E. R., D\u2019Souza, R. R., & Klampatsa, A. (2021). Armored CAR T-cells: The next chapter in T-cell cancer immunotherapy. Biologics\u202f: Targets & Therapy, 15, 95\u2013105.","journal-title":"Biologics : Targets & Therapy"},{"issue":"4","key":"10317_CR9","doi-asserted-by":"publisher","first-page":"2443","DOI":"10.3390\/cancers7040902","volume":"7","author":"K Shiga","year":"2015","unstructured":"Shiga, K., et al. (2015). Cancer-associated fibroblasts: Their characteristics and their roles in tumor growth. Cancers, 7(4), 2443\u20132458.","journal-title":"Cancers"},{"issue":"9","key":"10317_CR10","doi-asserted-by":"publisher","first-page":"2218","DOI":"10.1016\/j.ymthe.2018.07.005","volume":"26","author":"V Golumba-Nagy","year":"2018","unstructured":"Golumba-Nagy, V., et al. (2018). CD28-\u03b6 CAR T cells resist TGF-\u03b2 repression through IL-2 signaling, which can be mimicked by an engineered IL-7 autocrine loop. Molecular Therapy, 26(9), 2218\u20132230.","journal-title":"Molecular Therapy"},{"key":"10317_CR11","doi-asserted-by":"publisher","first-page":"1703","DOI":"10.1016\/B978-0-323-47674-4.00092-X","volume-title":"Abeloff\u2019s clinical oncology (sixth edition)","author":"JS Dome","year":"2020","unstructured":"Dome, J. S., et al. (2020). 92 - Pediatric solid tumors. In J. E. Niederhuber, et al. (Eds.), Abeloff\u2019s clinical oncology (sixth edition) (pp. 1703-1747.e11). Elsevier."},{"issue":"9","key":"10317_CR12","doi-asserted-by":"publisher","first-page":"2915","DOI":"10.1158\/1078-0432.CCR-18-1811","volume":"25","author":"YH Chen","year":"2019","unstructured":"Chen, Y. H., et al. (2019). Eradication of neuroblastoma by T cells redirected with an optimized GD2-specific chimeric antigen receptor and interleukin-15. Clinical Cancer Research, 25(9), 2915\u20132924.","journal-title":"Clinical Cancer Research"},{"issue":"16","key":"10317_CR13","doi-asserted-by":"publisher","first-page":"3564","DOI":"10.1158\/1078-0432.CCR-23-3157","volume":"30","author":"L Fischer-Riepe","year":"2024","unstructured":"Fischer-Riepe, L., et al. (2024). Preclinical development of CAR T cells with antigen-inducible IL18 enforcement to treat GD2-positive solid cancers. Clinical Cancer Research, 30(16), 3564\u20133577.","journal-title":"Clinical Cancer Research"},{"key":"10317_CR14","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.839783","volume":"13","author":"W Glienke","year":"2022","unstructured":"Glienke, W., et al. (2022). GMP-compliant manufacturing of TRUCKs: CAR T cells targeting GD(2) and releasing inducible IL-18. Frontiers in Immunology, 13, Article 839783.","journal-title":"Frontiers in Immunology"},{"key":"10317_CR15","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2021.734593","volume":"11","author":"G Li","year":"2021","unstructured":"Li, G., et al. (2021). IL-7 and CCR2b co-expression-mediated enhanced CAR-T survival and infiltration in solid tumors. Frontiers in Oncology, 11, Article 734593.","journal-title":"Frontiers in Oncology"},{"issue":"4","key":"10317_CR16","doi-asserted-by":"publisher","first-page":"448","DOI":"10.1038\/s41587-019-0398-2","volume":"38","author":"X Ma","year":"2020","unstructured":"Ma, X., et al. (2020). Interleukin-23 engineering improves CAR T cell function in solid tumors. Nature Biotechnology, 38(4), 448\u2013459.","journal-title":"Nature Biotechnology"},{"issue":"10","key":"10317_CR17","doi-asserted-by":"publisher","first-page":"990","DOI":"10.1038\/s43018-020-00119-y","volume":"1","author":"K Wang","year":"2020","unstructured":"Wang, K., et al. (2020). GD2-specific CAR T cells encapsulated in an injectable hydrogel control retinoblastoma and preserve vision. Nature Cancer, 1(10), 990\u2013997.","journal-title":"Nature Cancer"},{"key":"10317_CR18","first-page":"A134","volume":"9","author":"J Lake","year":"2021","unstructured":"Lake, J., et al. (2021). Co-opting IL-8 to enhance efficacy of B7H3 CAR T cells against pediatric sarcoma. Journal for Immunotherapy of Cancer, 9, A134\u2013A134.","journal-title":"Journal for Immunotherapy of Cancer"},{"issue":"19","key":"10317_CR19","doi-asserted-by":"publisher","first-page":"4434","DOI":"10.1158\/1078-0432.CCR-23-3298","volume":"30","author":"LJ Talbot","year":"2024","unstructured":"Talbot, L. J., et al. (2024). Redirecting B7-H3.CAR T cells to chemokines expressed in osteosarcoma enhances homing and antitumor activity in preclinical models. Clinical Cancer Research, 30(19), 4434\u20134449.","journal-title":"Clinical Cancer Research"},{"key":"10317_CR20","first-page":"A341","volume":"12","author":"B Moghimi","year":"2024","unstructured":"Moghimi, B., et al. (2024). Preclinical development of CTSR-armored B7H3 CAR-T cells for pediatric solid tumors. Journal for ImmunoTherapy of Cancer, 12, A341.","journal-title":"Journal for ImmunoTherapy of Cancer"},{"issue":"1","key":"10317_CR21","doi-asserted-by":"publisher","first-page":"9914","DOI":"10.1038\/s41467-025-64861-6","volume":"16","author":"EZ Song","year":"2025","unstructured":"Song, E. Z., et al. (2025). Engineered CXCR3-A expression enhances B7-H3-targeting CAR T cell migration and efficacy against diffuse intrinsic pontine glioma. Nature Communications, 16(1), 9914.","journal-title":"Nature Communications"},{"key":"10317_CR22","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2024.1462076","volume":"15","author":"X Hui","year":"2024","unstructured":"Hui, X., et al. (2024). A novel strategy of co-expressing CXCR5 and IL-7 enhances CAR-T cell effectiveness in osteosarcoma. Frontiers in Immunology, 15, Article 1462076.","journal-title":"Frontiers in Immunology"},{"issue":"SUPPL 2","key":"10317_CR23","first-page":"A118","volume":"9","author":"E Breman","year":"2021","unstructured":"Breman, E., et al. (2021). Armoring NKG2D car T cells with IL-18 improves in vivo anti-tumor activity. Journal for ImmunoTherapy of Cancer, 9(SUPPL 2), A118.","journal-title":"Journal for ImmunoTherapy of Cancer"},{"issue":"11","key":"10317_CR24","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1136\/jitc-2024-009743","volume":"12","author":"E Wickman","year":"2024","unstructured":"Wickman, E., et al. (2024). IL-18R supported CAR T cells targeting oncofetal tenascin C for the immunotherapy of pediatric sarcoma and brain tumors. Journal for Immunotherapy of Cancer, 12(11), 15.","journal-title":"Journal for Immunotherapy of Cancer"},{"key":"10317_CR25","doi-asserted-by":"publisher","DOI":"10.1158\/2326-6066.CIR-24-0975","author":"R Okada","year":"2025","unstructured":"Okada, R., et al. (2025). GPC2-targeted CAR T cells engineered with NFAT-inducible membrane-tethered IL-15\/IL-21 exhibit enhanced activity against neuroblastoma. Cancer Immunology Research. https:\/\/doi.org\/10.1158\/2326-6066.CIR-24-0975","journal-title":"Cancer Immunology Research"},{"issue":"11","key":"10317_CR26","doi-asserted-by":"publisher","first-page":"1686","DOI":"10.1038\/s41591-020-1074-2","volume":"26","author":"A Heczey","year":"2020","unstructured":"Heczey, A., et al. (2020). Anti-GD2 CAR-NKT cells in patients with relapsed or refractory neuroblastoma: An interim analysis. Nature Medicine, 26(11), 1686.","journal-title":"Nature Medicine"},{"issue":"23","key":"10317_CR27","doi-asserted-by":"publisher","first-page":"2769","DOI":"10.1200\/JCO.23.02019","volume":"42","author":"FY Lin","year":"2024","unstructured":"Lin, F. Y., et al. (2024). Phase I trial of GD2.CART cells augmented with constitutive interleukin-7 receptor for treatment of high-grade pediatric CNS tumors. Journal of Clinical Oncology, 42(23), 2769\u20132779.","journal-title":"Journal of Clinical Oncology"},{"issue":"8047","key":"10317_CR28","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1038\/s41586-024-08261-8","volume":"637","author":"D Steffin","year":"2025","unstructured":"Steffin, D., et al. (2025). Interleukin-15-armoured GPC3 CAR T cells for patients with solid cancers. Nature, 637(8047), 28.","journal-title":"Nature"},{"issue":"5","key":"10317_CR29","doi-asserted-by":"publisher","first-page":"493","DOI":"10.1007\/s10585-011-9384-x","volume":"28","author":"J PosthumaDeBoer","year":"2011","unstructured":"PosthumaDeBoer, J., et al. (2011). Molecular alterations as target for therapy in metastatic osteosarcoma: A review of literature. Clinical & Experimental Metastasis, 28(5), 493\u2013503.","journal-title":"Clinical & Experimental Metastasis"},{"issue":"5","key":"10317_CR30","doi-asserted-by":"publisher","first-page":"1100","DOI":"10.1002\/cncr.21263","volume":"104","author":"V Mialou","year":"2005","unstructured":"Mialou, V., et al. (2005). Metastatic osteosarcoma at diagnosis - Prognostic factors and long-term outcome - The French pediatric experience. Cancer, 104(5), 1100\u20131109.","journal-title":"Cancer"},{"issue":"3","key":"10317_CR31","doi-asserted-by":"publisher","first-page":"449","DOI":"10.1200\/JCO.1993.11.3.449","volume":"11","author":"PA Meyers","year":"1993","unstructured":"Meyers, P. A., et al. (1993). Osteogenic-sarcoma with clinically detectable metastasis at initial presentation. Journal of Clinical Oncology, 11(3), 449\u2013453.","journal-title":"Journal of Clinical Oncology"},{"key":"10317_CR32","doi-asserted-by":"crossref","unstructured":"Pezzella, M., et al., (2024)\u00a0Tumor-derived G-CSF induces an immunosuppressive microenvironment in an osteosarcoma model, reducing response to CAR.GD2 T-cells. Journal of Hematology & Oncology, 17(1):127.","DOI":"10.1186\/s13045-024-01641-7"},{"issue":"7","key":"10317_CR33","doi-asserted-by":"publisher","first-page":"697","DOI":"10.1182\/blood-2018-10-881722","volume":"133","author":"RM Sterner","year":"2019","unstructured":"Sterner, R. M., et al. (2019). GM-CSF inhibition reduces cytokine release syndrome and neuroinflammation but enhances CAR-T cell function in xenografts. Blood, 133(7), 697\u2013709.","journal-title":"Blood"},{"key":"10317_CR34","doi-asserted-by":"crossref","unstructured":"Ramakrishna, S., et al., (2022)\u00a0GD2.Ox40.CD28.z CAR T cell trial in neuroblastoma and osteosarcoma. Cancer Research,\u00a082(12):CT142","DOI":"10.1158\/1538-7445.AM2022-CT142"},{"issue":"1","key":"10317_CR35","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1007\/s10555-015-9552-6","volume":"34","author":"M Yan","year":"2015","unstructured":"Yan, M., et al. (2015). HER2 expression status in diverse cancers: Review of results from 37,992 patients. Cancer Metastasis Reviews, 34(1), 157\u201364.","journal-title":"Cancer Metastasis Reviews"},{"issue":"15","key":"10317_CR36","doi-asserted-by":"publisher","first-page":"1688","DOI":"10.1200\/JCO.2014.58.0225","volume":"33","author":"N Ahmed","year":"2015","unstructured":"Ahmed, N., et al. (2015). Human epidermal growth factor receptor 2 (HER2) -specific chimeric antigen receptor-modified T cells for the immunotherapy of HER2-positive sarcoma. Journal of Clinical Oncology, 33(15), 1688.","journal-title":"Journal of Clinical Oncology"},{"key":"10317_CR37","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1186\/s13046-018-0997-7","volume":"38","author":"YT Wang","year":"2019","unstructured":"Wang, Y. T., et al. (2019). Anti-CD166\/4-1BB chimeric antigen receptor T cell therapy for the treatment of osteosarcoma. Journal of Experimental & Clinical Cancer Research, 38, 11.","journal-title":"Journal of Experimental & Clinical Cancer Research"},{"issue":"4","key":"10317_CR38","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1007\/s10555-025-10294-y","volume":"44","author":"L Jansen","year":"2025","unstructured":"Jansen, L., et al. (2025). B7\u2013H3 in the tumor microenvironment: Implications for CAR T cell therapy in pediatric solid tumors. Cancer and Metastasis Reviews, 44(4), 77.","journal-title":"Cancer and Metastasis Reviews"},{"issue":"8","key":"10317_CR39","doi-asserted-by":"publisher","first-page":"1034","DOI":"10.1038\/cr.2017.90","volume":"27","author":"YH Lee","year":"2017","unstructured":"Lee, Y. H., et al. (2017). Inhibition of the B7-H3 immune checkpoint limits tumor growth by enhancing cytotoxic lymphocyte function. Cell Research, 27(8), 1034\u20131045.","journal-title":"Cell Research"},{"issue":"8","key":"10317_CR40","doi-asserted-by":"publisher","first-page":"2623","DOI":"10.1007\/s00262-023-03437-z","volume":"72","author":"L Hidalgo","year":"2023","unstructured":"Hidalgo, L., et al. (2023). Switchable CAR T cell strategy against osteosarcoma. Cancer Immunology, Immunotherapy, 72(8), 2623\u20132633.","journal-title":"Cancer Immunology, Immunotherapy"},{"issue":"8_Supplement_1","key":"10317_CR41","doi-asserted-by":"publisher","first-page":"3291","DOI":"10.1158\/1538-7445.AM2025-3291","volume":"85","author":"T Higgins","year":"2025","unstructured":"Higgins, T., & Agarwal, P. (2025). Abstract 3291: Development of anti-B7H3 CAR T cells for treatment of osteosarcoma in a canine model. Cancer Research, 85(8_Supplement_1), 3291\u20133291.","journal-title":"Cancer Research"},{"issue":"6","key":"10317_CR42","doi-asserted-by":"publisher","first-page":"539","DOI":"10.1016\/j.ccr.2007.04.017","volume":"11","author":"S Seaman","year":"2007","unstructured":"Seaman, S., et al. (2007). Genes that distinguish physiological and pathological angiogenesis. Cancer Cell, 11(6), 539\u2013554.","journal-title":"Cancer Cell"},{"issue":"17","key":"10317_CR43","doi-asserted-by":"publisher","first-page":"3754","DOI":"10.1158\/1078-0432.CCR-24-3083","volume":"31","author":"S Mehta","year":"2025","unstructured":"Mehta, S., et al. (2025). B7\u2013H3 CAR T cells are effective against ependymomas but limited by tumor size and immune response. Clinical Cancer Research, 31(17), 3754\u20133770.","journal-title":"Clinical Cancer Research"},{"issue":"1","key":"10317_CR44","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1186\/s12885-022-10229-8","volume":"22","author":"Q Zhang","year":"2022","unstructured":"Zhang, Q., et al. (2022). B7\u2013H3 targeted CAR-T cells show highly efficient anti-tumor function against osteosarcoma both in vitro and in vivo. BMC Cancer, 22(1), 12.","journal-title":"BMC Cancer"},{"key":"10317_CR45","doi-asserted-by":"publisher","first-page":"15","DOI":"10.3389\/fimmu.2021.691741","volume":"12","author":"LJ Talbot","year":"2021","unstructured":"Talbot, L. J., et al. (2021). A novel orthotopic implantation technique for osteosarcoma produces spontaneous metastases and illustrates dose-dependent efficacy of B7-H3-CAR T cells. Frontiers in Immunology, 12, 15.","journal-title":"Frontiers in Immunology"},{"key":"10317_CR46","unstructured":"Adeshakin, A., et al., (2024) Deletion of Regnase-1 enhances the antitumor activity of B7-H3-CAR T cells in an immunocompetent osteosarcoma model. Journal of Immunology, 212(1):1392-4466."},{"key":"10317_CR47","doi-asserted-by":"crossref","unstructured":"Adeshakin, A.O., et al., (2023) B7-H3-CAR T-cell therapy in immunecompetent osteosarcoma models: Regnase-1 KO overcomes limited CAR T-cell expansion. Cancer Research, 83(7):1778.","DOI":"10.1158\/1538-7445.AM2023-1778"},{"issue":"8","key":"10317_CR48","doi-asserted-by":"publisher","first-page":"2560","DOI":"10.1158\/1078-0432.CCR-18-0432","volume":"25","author":"RG Majzner","year":"2019","unstructured":"Majzner, R. G., et al. (2019). CAR T cells targeting B7\u2013H3, a pan-cancer antigen, demonstrate potent preclinical activity against pediatric solid tumors and brain tumors. Clinical Cancer Research, 25(8), 2560\u20132574.","journal-title":"Clinical Cancer Research"},{"key":"10317_CR49","doi-asserted-by":"publisher","DOI":"10.1200\/jco.2022.40.16","author":"NR Pinto","year":"2022","unstructured":"Pinto, N. R., et al. (2022). STRIVE-02: A first-in-human phase 1 trial of systemic B7H3 CAR T cells for children and young adults with relapsed\/refractory solid tumors. Journal of Clinical Oncology. https:\/\/doi.org\/10.1200\/jco.2022.40.16","journal-title":"Journal of Clinical Oncology"},{"key":"10317_CR50","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-023-39097-x","author":"N Mensali","year":"2023","unstructured":"Mensali, N., et al. (2023). ALPL-1 is a target for chimeric antigen receptor therapy in osteosarcoma. Nature Communications. https:\/\/doi.org\/10.1038\/s41467-023-39097-x","journal-title":"Nature Communications"},{"issue":"1","key":"10317_CR51","doi-asserted-by":"publisher","first-page":"271","DOI":"10.1158\/0008-5472.CAN-11-2778","volume":"72","author":"GX Huang","year":"2012","unstructured":"Huang, G. X., et al. (2012). Genetically modified T cells targeting interleukin-11 receptor \u03b1-chain kill human osteosarcoma cells and induce the regression of established osteosarcoma lung metastases. Cancer Research, 72(1), 271\u2013281.","journal-title":"Cancer Research"},{"issue":"7","key":"10317_CR52","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0133152","volume":"10","author":"X Huang","year":"2015","unstructured":"Huang, X., et al. (2015). IGF1R- and ROR1-specific CAR T cells as a potential therapy for high risk sarcomas. PLoS One, 10(7), Article e0133152.","journal-title":"PLoS One"},{"key":"10317_CR53","doi-asserted-by":"publisher","DOI":"10.3892\/mmr.2025.13608","author":"C Shin","year":"2025","unstructured":"Shin, C., et al. (2025). Chimeric PD\u20111 receptor redirects primary T cells against childhood solid tumors but not to PD\u20111 ligand\u2011positive CD80\u2011coexpressing cells. Molecular Medicine Reports. https:\/\/doi.org\/10.3892\/mmr.2025.13608","journal-title":"Molecular Medicine Reports"},{"issue":"19","key":"10317_CR54","doi-asserted-by":"publisher","first-page":"5824","DOI":"10.1158\/1078-0432.CCR-17-0075","volume":"23","author":"L Fern\u00e1ndez","year":"2017","unstructured":"Fern\u00e1ndez, L., et al. (2017). Memory T cells expressing an NKG2D-CAR efficiently target osteosarcoma cells. Clinical Cancer Research, 23(19), 5824\u20135835.","journal-title":"Clinical Cancer Research"},{"issue":"10","key":"10317_CR55","doi-asserted-by":"publisher","first-page":"1600","DOI":"10.1038\/mt.2015.119","volume":"23","author":"H VanSeggelen","year":"2015","unstructured":"VanSeggelen, H., et al. (2015). T cells engineered with chimeric antigen receptors targeting NKG2D ligands display lethal toxicity in mice. Molecular Therapy, 23(10), 1600\u20131610.","journal-title":"Molecular Therapy"},{"key":"10317_CR56","doi-asserted-by":"publisher","first-page":"15","DOI":"10.3389\/fimmu.2024.1462076","volume":"15","author":"XH Hui","year":"2024","unstructured":"Hui, X. H., et al. (2024). A novel strategy of co-expressing CXCR5 and IL-7 enhances CAR-T cell effectiveness in osteosarcoma. Frontiers in Immunology, 15, 15.","journal-title":"Frontiers in Immunology"},{"key":"10317_CR57","unstructured":"Durer, S., D. P. Gasalberti, & H. Shaikh. (2024). Ewing Sarcoma. In Statpearls [Internet]. Statpearls Publishing. Accessed Feb 2 2026."},{"issue":"6","key":"10317_CR58","doi-asserted-by":"publisher","first-page":"1123","DOI":"10.1038\/bjc.2012.57","volume":"106","author":"S Kailayangiri","year":"2012","unstructured":"Kailayangiri, S., et al. (2012). The ganglioside antigen GD2 is surface-expressed in Ewing sarcoma and allows for MHC-independent immune targeting. British Journal of Cancer, 106(6), 1123\u20131133.","journal-title":"British Journal of Cancer"},{"issue":"11","key":"10317_CR59","doi-asserted-by":"publisher","first-page":"3184","DOI":"10.1002\/ijc.32743","volume":"146","author":"M Charan","year":"2020","unstructured":"Charan, M., et al. (2020). GD2-directed CAR-T cells in combination with HGF-targeted neutralizing antibody (AMG102) prevent primary tumor growth and metastasis in Ewing sarcoma. International Journal of Cancer, 146(11), 3184\u20133195.","journal-title":"International Journal of Cancer"},{"issue":"1","key":"10317_CR60","doi-asserted-by":"publisher","first-page":"71","DOI":"10.3390\/biomedicines3010071","volume":"3","author":"A Spina","year":"2015","unstructured":"Spina, A., et al. (2015). HGF\/c-MET axis in tumor microenvironment and metastasis formation. Biomedicines, 3(1), 71\u201388.","journal-title":"Biomedicines"},{"issue":"4","key":"10317_CR61","doi-asserted-by":"publisher","first-page":"1344","DOI":"10.1158\/1078-0432.CCR-03-0038","volume":"10","author":"B Fuchs","year":"2004","unstructured":"Fuchs, B., Inwards, C. Y., & Janknecht, R. (2004). Vascular endothelial growth factor expression is up-regulated by EWS-ETS oncoproteins and Sp1 and may represent an independent predictor of survival in Ewing\u2019s sarcoma. Clinical Cancer Research, 10(4), 1344\u20131353.","journal-title":"Clinical Cancer Research"},{"issue":"12","key":"10317_CR62","doi-asserted-by":"publisher","first-page":"1904","DOI":"10.1016\/j.ejca.2006.01.063","volume":"42","author":"M Kreuter","year":"2006","unstructured":"Kreuter, M., et al. (2006). Clinical significance of Vascular Endothelial Growth Factor-A expression in Ewing\u2019s sarcoma. European Journal of Cancer, 42(12), 1904\u20131911.","journal-title":"European Journal of Cancer"},{"issue":"6","key":"10317_CR63","doi-asserted-by":"publisher","first-page":"2364","DOI":"10.1158\/1078-0432.CCR-04-1201","volume":"11","author":"S Dalal","year":"2005","unstructured":"Dalal, S., et al. (2005). Vascular endothelial growth factor: A therapeutic target for tumors of the Ewing\u2019s sarcoma family. Clinical Cancer Research, 11(6), 2364\u201378.","journal-title":"Clinical Cancer Research"},{"issue":"10","key":"10317_CR64","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1002\/pbc.28313","volume":"67","author":"A Englisch","year":"2020","unstructured":"Englisch, A., et al. (2020). VEGFR2 as a target for CAR T cell therapy of Ewing sarcoma. Pediatric Blood & Cancer, 67(10), 11.","journal-title":"Pediatric Blood & Cancer"},{"key":"10317_CR65","doi-asserted-by":"crossref","unstructured":"Funasaka, C., et al., (2025) Trial in progress: Phase I study of non-viral gene-modified CAR-T cell therapy for malignant solid tumors expressing EPHB4 receptor (CARTiEr). Frontiers in Oncology,\u00a015:1633324.","DOI":"10.3389\/fonc.2025.1633324"},{"issue":"8","key":"10317_CR66","doi-asserted-by":"publisher","first-page":"2142","DOI":"10.1038\/bjc.2013.578","volume":"109","author":"J Posthumadeboer","year":"2013","unstructured":"Posthumadeboer, J., et al. (2013). Surface proteomic analysis of osteosarcoma identifies EPHA2 as receptor for targeted drug delivery. British Journal of Cancer, 109(8), 2142\u20132154.","journal-title":"British Journal of Cancer"},{"issue":"6","key":"10317_CR67","doi-asserted-by":"publisher","first-page":"836","DOI":"10.1111\/j.1365-2559.2010.03713.x","volume":"57","author":"R Fritsche-Guenther","year":"2010","unstructured":"Fritsche-Guenther, R., et al. (2010). De novo expression of EphA2 in osteosarcoma modulates activation of the mitogenic signalling pathway. Histopathology, 57(6), 836\u2013850.","journal-title":"Histopathology"},{"issue":"3\u20134","key":"10317_CR68","doi-asserted-by":"publisher","first-page":"321","DOI":"10.1038\/s41417-020-00221-4","volume":"28","author":"K Hsu","year":"2021","unstructured":"Hsu, K., et al. (2021). Chimeric antigen receptor-modified T cells targeting EphA2 for the immunotherapy of paediatric bone tumours. Cancer Gene Therapy, 28(3\u20134), 321\u2013334.","journal-title":"Cancer Gene Therapy"},{"issue":"2","key":"10317_CR69","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1186\/bcr2251","volume":"11","author":"RA Hancox","year":"2009","unstructured":"Hancox, R. A., et al. (2009). Tumour-associated tenascin-C isoforms promote breast cancer cell invasion and growth by matrix metalloproteinase-dependent and independent mechanisms. Breast Cancer Research, 11(2), 13.","journal-title":"Breast Cancer Research"},{"issue":"6","key":"10317_CR70","doi-asserted-by":"publisher","first-page":"883","DOI":"10.1091\/mbc.7.6.883","volume":"7","author":"CY Chung","year":"1996","unstructured":"Chung, C. Y., MurphyUllrich, J. E., & Erickson, H. P. (1996). Mitogenesis, cell migration, and loss of focal adhesions induced by tenascin-C interacting with its cell surface receptor, annexin II. Molecular Biology of the Cell, 7(6), 883\u2013892.","journal-title":"Molecular Biology of the Cell"},{"issue":"9","key":"10317_CR71","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1172\/jci166028","volume":"133","author":"JE Jaspers","year":"2023","unstructured":"Jaspers, J. E., et al. (2023). IL-18-secreting CAR T cells targeting DLL3 are highly effective in small cell lung cancer models. Journal of Clinical Investigation, 133(9), 12.","journal-title":"Journal of Clinical Investigation"},{"key":"10317_CR72","doi-asserted-by":"publisher","DOI":"10.3390\/cancers14030814","author":"K Nakamura","year":"2022","unstructured":"Nakamura, K., et al. (2022). GPR64, screened from Ewing sarcoma cells, is a potential target for antibody-based therapy for various sarcomas. Cancers (Basel). https:\/\/doi.org\/10.3390\/cancers14030814","journal-title":"Cancers (Basel)"},{"key":"10317_CR73","first-page":"130","volume":"41","author":"D Schirmer","year":"2018","unstructured":"Schirmer, D., et al. (2018). GPR64-specific CAR-trnasgenic T cells selectively kill Ewing sarcoma cells. Oncology Research and Treatment, 41, 130.","journal-title":"Oncology Research and Treatment"},{"issue":"10","key":"10317_CR74","doi-asserted-by":"publisher","first-page":"1122","DOI":"10.1016\/j.jcyt.2024.05.011","volume":"26","author":"D Lutskovich","year":"2024","unstructured":"Lutskovich, D., Meleshko, A., & Katsin, M. (2024). State of the art and perspectives of chimeric antigen receptor T cells cell therapy for neuroblastoma. Cytotherapy, 26(10), 1122\u20131131.","journal-title":"Cytotherapy"},{"issue":"23","key":"10317_CR75","doi-asserted-by":"publisher","first-page":"2202","DOI":"10.1056\/NEJMra0804577","volume":"362","author":"JM Maris","year":"2010","unstructured":"Maris, J. M. (2010). Recent advances in neuroblastoma. The New England Journal of Medicine, 362(23), 2202\u201311.","journal-title":"The New England Journal of Medicine"},{"key":"10317_CR76","unstructured":"Mahapatra, S., & Challagundla, K. B. (2025). Neuroblastoma. StatPearls. StatPearls Publishing. Copyright \u00a9 2025, StatPearls Publishing LLC.: Treasure Island (FL) ineligible companies. Disclosure: Kishore Challagundla declares no relevant financial relationships with ineligible companies."},{"issue":"10","key":"10317_CR77","doi-asserted-by":"publisher","first-page":"2643","DOI":"10.1007\/s00432-021-03839-5","volume":"148","author":"L Yu","year":"2022","unstructured":"Yu, L., et al. (2022). GD2-specific chimeric antigen receptor-modified T cells for the treatment of refractory and\/or recurrent neuroblastoma in pediatric patients. Journal of Cancer Research and Clinical Oncology, 148(10), 2643\u20132652.","journal-title":"Journal of Cancer Research and Clinical Oncology"},{"key":"10317_CR78","first-page":"205","volume":"15","author":"WL Furman","year":"2021","unstructured":"Furman, W. L. (2021). Monoclonal antibody therapies for high risk neuroblastoma. Biologics\u202f: Targets and Therapy, 15, 205\u2013219.","journal-title":"Biologics : Targets and Therapy"},{"issue":"11","key":"10317_CR79","doi-asserted-by":"publisher","first-page":"1264","DOI":"10.1038\/nm.1882","volume":"14","author":"MA Pule","year":"2008","unstructured":"Pule, M. A., et al. (2008). Virus-specific T cells engineered to coexpress tumor-specific receptors: Persistence and antitumor activity in individuals with neuroblastoma. Nature Medicine, 14(11), 1264\u20131270.","journal-title":"Nature Medicine"},{"issue":"23","key":"10317_CR80","doi-asserted-by":"publisher","first-page":"6050","DOI":"10.1182\/blood-2011-05-354449","volume":"118","author":"CU Louis","year":"2011","unstructured":"Louis, C. U., et al. (2011). Antitumor activity and long-term fate of chimeric antigen receptor-positive T cells in patients with neuroblastoma. Blood, 118(23), 6050\u20136056.","journal-title":"Blood"},{"issue":"4","key":"10317_CR81","doi-asserted-by":"publisher","first-page":"1125","DOI":"10.1038\/s41591-025-03513-0","volume":"31","author":"CH Li","year":"2025","unstructured":"Li, C. H., et al. (2025). Long-term outcomes of GD2-directed CAR-T cell therapy in patients with neuroblastoma. Nature Medicine, 31(4), 1125\u20131129.","journal-title":"Nature Medicine"},{"issue":"14","key":"10317_CR82","doi-asserted-by":"publisher","first-page":"1284","DOI":"10.1056\/NEJMoa2210859","volume":"388","author":"F Del Bufalo","year":"2023","unstructured":"Del Bufalo, F., et al. (2023). GD2-CART01 for relapsed or refractory high-risk neuroblastoma. New England Journal of Medicine, 388(14), 1284\u20131295.","journal-title":"New England Journal of Medicine"},{"key":"10317_CR83","doi-asserted-by":"crossref","unstructured":"Locatelli, F., et al., (2025)\u00a0GD2-targeting CAR T cells in high-risk neuroblastoma: A phase 1\/phase 2 trial. Nature Medicine,\u00a031(11):3689-3699.","DOI":"10.1038\/s41591-025-03874-6"},{"key":"10317_CR84","doi-asserted-by":"publisher","DOI":"10.1186\/s13045-021-01193-0","author":"N Tumino","year":"2021","unstructured":"Tumino, N., et al. (2021). Polymorphonuclear myeloid-derived suppressor cells impair the anti-tumor efficacy of GD2.CAR T-cells in patients with neuroblastoma. Journal of Hematology & Oncology. https:\/\/doi.org\/10.1186\/s13045-021-01193-0","journal-title":"Journal of Hematology & Oncology"},{"issue":"3","key":"10317_CR85","doi-asserted-by":"publisher","first-page":"849","DOI":"10.1038\/s41591-024-03449-x","volume":"31","author":"C Quintarelli","year":"2025","unstructured":"Quintarelli, C., et al. (2025). Donor-derived GD2-specific CAR T cells in relapsed or refractory neuroblastoma. Nature Medicine, 31(3), 849\u2013860.","journal-title":"Nature Medicine"},{"issue":"9","key":"10317_CR86","doi-asserted-by":"publisher","first-page":"2214","DOI":"10.1016\/j.ymthe.2017.05.012","volume":"25","author":"A Heczey","year":"2017","unstructured":"Heczey, A., et al. (2017). CAR T cells administered in combination with lymphodepletion and PD-1 inhibition to patients with neuroblastoma. Molecular Therapy, 25(9), 2214\u20132224.","journal-title":"Molecular Therapy"},{"issue":"571","key":"10317_CR87","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.abd6169","volume":"12","author":"K Straathof","year":"2020","unstructured":"Straathof, K., et al. (2020). Antitumor activity without on-target off-tumor toxicity of GD2-chimeric antigen receptor T cells in patients with neuroblastoma. Science Translational Medicine, 12(571), Article 12.","journal-title":"Science Translational Medicine"},{"key":"10317_CR88","doi-asserted-by":"publisher","DOI":"10.3390\/cancers15133279","author":"C Bottino","year":"2023","unstructured":"Bottino, C., et al. (2023). B7-H3 in pediatric tumors: Far beyond neuroblastoma. Cancers (Basel). https:\/\/doi.org\/10.3390\/cancers15133279","journal-title":"Cancers (Basel)"},{"issue":"2","key":"10317_CR89","doi-asserted-by":"publisher","first-page":"221","DOI":"10.1016\/j.ccell.2019.01.002","volume":"35","author":"HW Du","year":"2019","unstructured":"Du, H. W., et al. (2019). Antitumor responses in the absence of toxicity in solid tumors by targeting B7-H3 via chimeric antigen receptor T cells. Cancer Cell, 35(2), 221.","journal-title":"Cancer Cell"},{"key":"10317_CR90","doi-asserted-by":"publisher","first-page":"429","DOI":"10.1016\/j.omto.2022.08.008","volume":"26","author":"K Birley","year":"2022","unstructured":"Birley, K., et al. (2022). A novel anti-B7-H3 chimeric antigen receptor from a single-chain antibody library for immunotherapy of solid cancers. Molecular Therapy Oncolytics, 26, 429\u2013443.","journal-title":"Molecular Therapy Oncolytics"},{"issue":"3","key":"10317_CR91","doi-asserted-by":"publisher","first-page":"295","DOI":"10.1016\/j.ccell.2017.08.003","volume":"32","author":"KR Bosse","year":"2017","unstructured":"Bosse, K. R., et al. (2017). Identification of GPC2 as an oncoprotein and candidate immunotherapeutic target in high-risk neuroblastoma. Cancer Cell, 32(3), 295-309.e12.","journal-title":"Cancer Cell"},{"issue":"16","key":"10317_CR92","doi-asserted-by":"publisher","first-page":"3578","DOI":"10.1158\/1078-0432.CCR-24-0221","volume":"30","author":"G Pascual-Pasto","year":"2024","unstructured":"Pascual-Pasto, G., et al. (2024). Targeting GPC2 on intraocular and CNS metastatic retinoblastomas with local and systemic delivery of CAR T cells. Clinical Cancer Research, 30(16), 3578\u20133591.","journal-title":"Clinical Cancer Research"},{"issue":"1","key":"10317_CR93","doi-asserted-by":"publisher","first-page":"7141","DOI":"10.1038\/s41467-024-51337-2","volume":"15","author":"G Pascual-Pasto","year":"2024","unstructured":"Pascual-Pasto, G., et al. (2024). CAR T-cell-mediated delivery of bispecific innate immune cell engagers for neuroblastoma. Nature Communications, 15(1), 7141.","journal-title":"Nature Communications"},{"issue":"SUPPL 2","key":"10317_CR94","first-page":"S88","volume":"69","author":"N Booth","year":"2022","unstructured":"Booth, N., et al. (2022). Receptor tyrosine kinase-like orphan receptor-2: A novel cellular therapy target for neuroblastoma. Pediatric Blood and Cancer, 69(SUPPL 2), S88\u2013S89.","journal-title":"Pediatric Blood and Cancer"},{"key":"10317_CR95","doi-asserted-by":"crossref","unstructured":"Buhl, J.L., et al., (2025) Cell surface proteomics of patient-derived malignant rhabdoid tumor organoids identifies ROBO1 as potential CAR T cell target for pediatric solid tumors.\u00a0bioRxiv 2025.02.23.639405.","DOI":"10.1101\/2025.02.23.639405"},{"issue":"12","key":"10317_CR96","doi-asserted-by":"publisher","first-page":"2100","DOI":"10.1016\/j.ccell.2023.11.004","volume":"41","author":"E Bergaggio","year":"2023","unstructured":"Bergaggio, E., et al. (2023). ALK inhibitors increase ALK expression and sensitize neuroblastoma cells to ALK.CAR-T cells. Cancer Cell, 41(12), 2100-2116.e10.","journal-title":"Cancer Cell"},{"issue":"21\u201322","key":"10317_CR97","first-page":"A16","volume":"34","author":"L Clares-Villa","year":"2023","unstructured":"Clares-Villa, L., et al. (2023). Turning NKG2D CAR-T therapy into an improved IL18 truck as a treatment for pediatric central nervous system tumors. Human Gene Therapy Methods, 34(21\u201322), A16.","journal-title":"Human Gene Therapy Methods"},{"issue":"8","key":"10317_CR98","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1007\/s11940-019-0577-y","volume":"21","author":"NA Vitanza","year":"2019","unstructured":"Vitanza, N. A., & Monje, M. (2019). Diffuse intrinsic pontine glioma: From diagnosis to next-generation clinical trials. Current Treatment Options in Neurology, 21(8), 37.","journal-title":"Current Treatment Options in Neurology"},{"issue":"7903","key":"10317_CR99","doi-asserted-by":"publisher","first-page":"934","DOI":"10.1038\/s41586-022-04489-4","volume":"603","author":"RG Majzner","year":"2022","unstructured":"Majzner, R. G., et al. (2022). GD2-CART cell therapy for H3K27M-mutated diffuse midline gliomas. Nature, 603(7903), 934.","journal-title":"Nature"},{"issue":"8046","key":"10317_CR100","doi-asserted-by":"publisher","first-page":"708","DOI":"10.1038\/s41586-024-08171-9","volume":"637","author":"M Monje","year":"2025","unstructured":"Monje, M., et al. (2025). Intravenous and intracranial GD2-CAR T cells for H3K27M+ diffuse midline gliomas. Nature, 637(8046), 708\u2013715.","journal-title":"Nature"},{"issue":"7","key":"10317_CR101","doi-asserted-by":"publisher","first-page":"1150","DOI":"10.1093\/neuonc\/noab300","volume":"24","author":"E De Billy","year":"2022","unstructured":"De Billy, E., et al. (2022). Dual IGF1R\/IR inhibitors in combination with GD2-CAR T-cells display a potent anti-tumor activity in diffuse midline glioma H3K27M-mutant. Neuro-Oncology, 24(7), 1150\u20131163.","journal-title":"Neuro-Oncology"},{"issue":"3","key":"10317_CR102","doi-asserted-by":"publisher","first-page":"861","DOI":"10.1038\/s41591-024-03451-3","volume":"31","author":"NA Vitanza","year":"2025","unstructured":"Vitanza, N. A., et al. (2025). Intracerebroventricular B7-H3-targeting CAR T cells for diffuse intrinsic pontine glioma: A phase 1 trial. Nature Medicine, 31(3), 861\u2013868.","journal-title":"Nature Medicine"},{"key":"10317_CR103","doi-asserted-by":"crossref","unstructured":"Timpanaro, A., et al., (2025)\u00a0Preclinical efficacy of combinatorial B7-H3 CAR T cell and ONC206 treatment in DIPG\/DMG. Cancer Research, 85(8):6400.","DOI":"10.1158\/1538-7445.AM2025-6400"},{"key":"10317_CR104","doi-asserted-by":"publisher","DOI":"10.1093\/neuonc\/noad073.200","volume":"25","author":"C Myers","year":"2023","unstructured":"Myers, C., et al. (2023). Preclinical efficacy of multi-antigen (HER2\/EGFR806\/B7-H3\/IL13RA2) targeting QUAD-CAR T cells against diffuse midline glioma. Neuro-Oncology, 25, Article i52.","journal-title":"Neuro-Oncology"},{"key":"10317_CR105","doi-asserted-by":"crossref","unstructured":"Ronsley, R., et al., (2024) Pioneering QUAD-targeting CAR T cell therapy in pediatric CNS tumors - Analysis from the initial patients treated on the first-in-human phase 1 trial Brainchild-04. Neuro-Oncology, 26:viii84.","DOI":"10.1093\/neuonc\/noae165.0336"},{"key":"10317_CR106","doi-asserted-by":"publisher","DOI":"10.1093\/noajnl\/vdad024","author":"SS Wang","year":"2023","unstructured":"Wang, S. S., et al. (2023). HER2 chimeric antigen receptor T cell immunotherapy is an effective treatment for diffuse intrinsic pontine glioma. Neuro-Oncology Advances. https:\/\/doi.org\/10.1093\/noajnl\/vdad024","journal-title":"Neuro-Oncology Advances"},{"key":"10317_CR107","doi-asserted-by":"publisher","DOI":"10.1093\/neuonc\/noac079.307","volume":"24","author":"L Ferrerosa","year":"2022","unstructured":"Ferrerosa, L., et al. (2022). Synnotch chimeric antigen receptor (CAR) T-cells as a potential treatment for diffuse intrinsic pontine glioma (DIPG)\/diffuse midline glioma (DMG). Neuro-Oncology, 24, Article i84.","journal-title":"Neuro-Oncology"},{"key":"10317_CR108","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2021-004450","author":"JB Foster","year":"2022","unstructured":"Foster, J. B., et al. (2022). Development of GPC2-directed chimeric antigen receptors using mRNA for pediatric brain tumors. Journal for ImmunoTherapy of Cancer. https:\/\/doi.org\/10.1136\/jitc-2021-004450","journal-title":"Journal for ImmunoTherapy of Cancer"},{"issue":"1","key":"10317_CR109","doi-asserted-by":"publisher","first-page":"19381","DOI":"10.1038\/s41598-022-23944-w","volume":"12","author":"Y Kubota","year":"2022","unstructured":"Kubota, Y., et al. (2022). Surrogacy analysis of intermediate end-points for overall survival in randomized controlled trials of rhabdomyosarcoma. Scientific Reports, 12(1), 19381.","journal-title":"Scientific Reports"},{"key":"10317_CR110","doi-asserted-by":"publisher","DOI":"10.3390\/cancers13184528","author":"RR Lavoie","year":"2021","unstructured":"Lavoie, R. R., et al. (2021). Surfaceome profiling of rhabdomyosarcoma reveals B7-H3 as a mediator of immune evasion. Cancers (Basel). https:\/\/doi.org\/10.3390\/cancers13184528","journal-title":"Cancers (Basel)"},{"key":"10317_CR111","doi-asserted-by":"crossref","unstructured":"Piccand, C., et al., (2025)\u00a0Improving CAR T cell potency against low-density targets in rhabdomyosarcoma. Cancer Research, 85(8):6110.","DOI":"10.1158\/1538-7445.AM2025-6110"},{"issue":"6","key":"10317_CR112","doi-asserted-by":"publisher","first-page":"673","DOI":"10.1038\/89044","volume":"7","author":"J Khan","year":"2001","unstructured":"Khan, J., et al. (2001). Classification and diagnostic prediction of cancers using gene expression profiling and artificial neural networks. Nature Medicine, 7(6), 673\u2013679.","journal-title":"Nature Medicine"},{"issue":"Suppl 9","key":"10317_CR113","doi-asserted-by":"publisher","first-page":"2093","DOI":"10.1002\/cncr.32764","volume":"126","author":"W Xiao","year":"2020","unstructured":"Xiao, W., et al. (2020). Chimeric antigen receptor-modified T-cell therapy for platelet-derived growth factor receptor \u03b1-positive rhabdomyosarcoma. Cancer, 126(Suppl 9), 2093\u20132100.","journal-title":"Cancer"},{"issue":"10","key":"10317_CR114","doi-asserted-by":"publisher","first-page":"1571","DOI":"10.1038\/s41417-024-00823-2","volume":"31","author":"W Xiao","year":"2024","unstructured":"Xiao, W., et al. (2024). FGFR4-specific CAR-T cells with inducible caspase-9 suicide gene as an approach to treat rhabdomyosarcoma. Cancer Gene Therapy, 31(10), 1571\u20131584.","journal-title":"Cancer Gene Therapy"},{"key":"10317_CR115","doi-asserted-by":"crossref","unstructured":"Cheuk, A., et al.,\u00a0(2020) Development of FGFR4-specific chimeric antibody receptor (CAR) T cell and bispecific T cell engager (BiTE) for rhabdomyosarcoma (RMS) immunotherapy. Cancer Research, 80(14 SUPPL):A08.","DOI":"10.1158\/1538-7445.PEDCA19-A08"},{"issue":"11","key":"10317_CR116","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3390\/cancers12113313","volume":"12","author":"N Alijaj","year":"2020","unstructured":"Alijaj, N., et al. (2020). Novel FGFR4-targeting single-domain antibodies for multiple targeted therapies against rhabdomyosarcoma. Cancers, 12(11), 1\u201322.","journal-title":"Cancers"},{"key":"10317_CR117","doi-asserted-by":"crossref","unstructured":"Sullivan, P., et al., (2021) Development of FGFR4-targeted chimeric antigen receptors (CARs) for the treatment of rhabdomyosarcoma. Cancer Research, 81(13 SUPPL):1545.","DOI":"10.1158\/1538-7445.AM2021-1545"},{"issue":"10","key":"10317_CR118","doi-asserted-by":"publisher","first-page":"1608","DOI":"10.1158\/1535-7163.MCT-22-0059","volume":"21","author":"PM Sullivan","year":"2022","unstructured":"Sullivan, P. M., et al. (2022). FGFR4-targeted chimeric antigen receptors combined with anti-myeloid polypharmacy effectively treat orthotopic rhabdomyosarcoma. Molecular Cancer Therapeutics, 21(10), 1608\u20131621.","journal-title":"Molecular Cancer Therapeutics"},{"issue":"1","key":"10317_CR119","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1038\/s41467-023-44432-3","volume":"15","author":"MJ Tian","year":"2024","unstructured":"Tian, M. J., et al. (2024). CAR T-cells targeting FGFR4 and CD276 simultaneously show potent antitumor effect against childhood rhabdomyosarcoma. Nature Communications, 15(1), 17.","journal-title":"Nature Communications"},{"issue":"1","key":"10317_CR120","doi-asserted-by":"publisher","first-page":"293","DOI":"10.1186\/s13046-023-02838-3","volume":"42","author":"A Timpanaro","year":"2023","unstructured":"Timpanaro, A., et al. (2023). CD276-CAR T cells and dual-CAR T cells targeting CD276\/FGFR4 promote rhabdomyosarcoma clearance in orthotopic mouse models. Journal of Experimental & Clinical Cancer Research\u202f: J Exp Clin Cancer Res, 42(1), 293.","journal-title":"Journal of Experimental & Clinical Cancer Research : J Exp Clin Cancer Res"},{"issue":"1","key":"10317_CR121","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1002\/gcc.22996","volume":"61","author":"S Mitra","year":"2022","unstructured":"Mitra, S., et al. (2022). Amplification of ERBB2 (HER2) in embryonal rhabdomyosarcoma: A potential treatment target in rare cases? Genes, Chromosomes & Cancer, 61(1), 5\u20139.","journal-title":"Genes, Chromosomes & Cancer"},{"key":"10317_CR122","first-page":"A420","volume":"10","author":"A Lulu","year":"2022","unstructured":"Lulu, A., et al. (2022). Developing a new targeted therapy for pediatric rhabdomyosarcoma: AVb3 and HER2 as promising targets for bispecific CAR T-cell therapy. Journal for ImmunoTherapy of Cancer, 10, A420\u2013A421.","journal-title":"Journal for ImmunoTherapy of Cancer"},{"key":"10317_CR123","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtct.2025.01.308","author":"AM Lulu","year":"2025","unstructured":"Lulu, A. M., et al. (2025). Acquired CAR-T therapy resistance in a pre-clinical model of pediatric rhabdomyosarcoma minimal residual disease. Transplantation and Cellular Therapy. https:\/\/doi.org\/10.1016\/j.jtct.2025.01.308","journal-title":"Transplantation and Cellular Therapy"},{"issue":"6","key":"10317_CR124","doi-asserted-by":"publisher","first-page":"880","DOI":"10.1038\/s43018-024-00749-6","volume":"5","author":"M Hegde","year":"2024","unstructured":"Hegde, M., et al. (2024). Autologous HER2-specific CAR T cells after lymphodepletion for advanced sarcoma: A phase 1 trial. Nature Cancer, 5(6), 880\u2013894.","journal-title":"Nature Cancer"},{"issue":"1","key":"10317_CR125","doi-asserted-by":"publisher","first-page":"3549","DOI":"10.1038\/s41467-020-17175-8","volume":"11","author":"M Hegde","year":"2020","unstructured":"Hegde, M., et al. (2020). Tumor response and endogenous immune reactivity after administration of HER2 CAR T cells in a child with metastatic rhabdomyosarcoma. Nature Communications, 11(1), 3549.","journal-title":"Nature Communications"},{"key":"10317_CR126","doi-asserted-by":"publisher","DOI":"10.1097\/MD.0000000000017572","author":"C Jiang","year":"2019","unstructured":"Jiang, C., et al. (2019). CD56-chimeric antigen receptor T-cell therapy for refractory\/recurrent rhabdomyosarcoma: A 3.5-year follow-up case report. Medicine (Baltimore). https:\/\/doi.org\/10.1097\/MD.0000000000017572","journal-title":"Medicine (Baltimore)"},{"key":"10317_CR127","doi-asserted-by":"crossref","unstructured":"Shraim, R., et al.,\u00a0(2024) GPC2 directed CAR T cells are efficacious against fusion-positive and fusion-negative rhabdomyosarcomas. Cancer Research, 84(6):1090.","DOI":"10.1158\/1538-7445.AM2024-1090"},{"issue":"9","key":"10317_CR128","doi-asserted-by":"publisher","first-page":"1129","DOI":"10.1136\/bjo.2008.150292","volume":"93","author":"T Kivel\u00e4","year":"2009","unstructured":"Kivel\u00e4, T. (2009). The epidemiological challenge of the most frequent eye cancer: Retinoblastoma, an issue of birth and death. British Journal of Ophthalmology, 93(9), 1129\u20131131.","journal-title":"British Journal of Ophthalmology"},{"issue":"2","key":"10317_CR129","first-page":"197","volume":"6","author":"SE Soliman","year":"2017","unstructured":"Soliman, S. E., et al. (2017). Genetics and molecular diagnostics in retinoblastoma\u2013An update. Asia Pac J Ophthalmol (Phila), 6(2), 197\u2013207.","journal-title":"Asia Pac J Ophthalmol (Phila)"},{"issue":"1","key":"10317_CR130","doi-asserted-by":"publisher","first-page":"895","DOI":"10.1186\/s12885-019-6131-1","volume":"19","author":"L Andersch","year":"2019","unstructured":"Andersch, L., et al. (2019). CD171- and GD2-specific CAR-T cells potently target retinoblastoma cells in preclinical in vitro testing. BMC Cancer, 19(1), 895.","journal-title":"BMC Cancer"},{"issue":"2","key":"10317_CR131","doi-asserted-by":"publisher","DOI":"10.1016\/j.tranon.2020.100971","volume":"14","author":"J Sujjitjoon","year":"2021","unstructured":"Sujjitjoon, J., et al. (2021). GD2-specific chimeric antigen receptor-modified T cells targeting retinoblastoma - Assessing tumor and T cell interaction. Translational Oncology, 14(2), Article 100971.","journal-title":"Translational Oncology"},{"issue":"7","key":"10317_CR132","doi-asserted-by":"publisher","first-page":"1210","DOI":"10.1002\/pbc.23090","volume":"57","author":"AM Termuhlen","year":"2011","unstructured":"Termuhlen, A. M., et al. (2011). Twenty-five year follow-up of childhood Wilms tumor: A report from the Childhood Cancer Survivor Study. Pediatric Blood & Cancer, 57(7), 1210\u20131216.","journal-title":"Pediatric Blood & Cancer"},{"key":"10317_CR133","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2022.40.16_suppl.2541","author":"CM Albert","year":"2022","unstructured":"Albert, C. M., et al. (2022). STRIvE-01: Phase I study of EGFR806 CAR T-cell immunotherapy for recurrent\/ refractory solid tumors in children and young adults. Journal of Clinical Oncology. https:\/\/doi.org\/10.1200\/JCO.2022.40.16_suppl.2541","journal-title":"Journal of Clinical Oncology"},{"issue":"4","key":"10317_CR134","first-page":"212","volume":"28","author":"DHM Steffin","year":"2020","unstructured":"Steffin, D. H. M., et al. (2020). A phase 1 clinical trial using armored GPC3-Car T cells for children with relapsed\/refractory liver tumors. Molecular Therapy, 28(4), 212\u2013213.","journal-title":"Molecular Therapy"},{"key":"10317_CR135","doi-asserted-by":"publisher","DOI":"10.3390\/cancers17060920","author":"L Seidmann","year":"2025","unstructured":"Seidmann, L., et al. (2025). The chimeric antigen receptor T cell target Claudin 6 is a marker for early organ-specific epithelial progenitors and is expressed in some pediatric solid tumor entities. Cancers (Basel). https:\/\/doi.org\/10.3390\/cancers17060920","journal-title":"Cancers (Basel)"},{"issue":"12","key":"10317_CR136","doi-asserted-by":"publisher","first-page":"3120","DOI":"10.1002\/1097-0142(20011215)92:12<3120::AID-CNCR10173>3.0.CO;2-2","volume":"92","author":"MA Ghanem","year":"2001","unstructured":"Ghanem, M. A., et al. (2001). Expression and prognostic value of epidermal growth factor receptor, transforming growth factor-alpha, and c-erb B-2 in nephroblastoma. Cancer, 92(12), 3120\u20133129.","journal-title":"Cancer"},{"issue":"26","key":"10317_CR137","doi-asserted-by":"publisher","first-page":"2531","DOI":"10.1056\/NEJMoa1707447","volume":"377","author":"SS Neelapu","year":"2017","unstructured":"Neelapu, S. S., et al. (2017). Axicabtagene ciloleucel CAR T-Cell Therapy in refractory large B-CellLymphoma. New England Journal of Medicine, 377(26), 2531\u20132544.","journal-title":"New England Journal of Medicine"},{"key":"10317_CR138","doi-asserted-by":"crossref","unstructured":"Schuster, S.J., et al. (2017). Chimeric antigen receptor t cells in refractory B-cell lymphomas. New England Journal of Medicine, 377(26), 2545\u20132554.","DOI":"10.1056\/NEJMoa1708566"},{"key":"10317_CR139","doi-asserted-by":"crossref","unstructured":"Grupp, S.A., et al. (2013). Chimeric antigen receptor\u2013modified T cells for acute lymphoid leukemia. New England Journal of Medicine, 368(16), 1509\u20131518.","DOI":"10.1056\/NEJMoa1215134"},{"issue":"8","key":"10317_CR140","doi-asserted-by":"publisher","first-page":"725","DOI":"10.1056\/NEJMoa1103849","volume":"365","author":"DL Porter","year":"2011","unstructured":"Porter, D. L., et al. (2011). Chimeric antigen receptor-modified T cells in chronic lymphoid leukemia. The New England Journal of Medicine, 365(8), 725\u2013733.","journal-title":"The New England Journal of Medicine"},{"key":"10317_CR141","doi-asserted-by":"crossref","unstructured":"Kirtane, K., et al., (2025) Logic-gated, allogeneic Tmod chimeric antigen receptor T-cell (CAR T) therapy targeting epidermal growth factor receptor (EGFR) in advanced solid tumors with human leukocyte antigen (HLA) loss of heterozygosity (LOH): DENALI-1 trial. Journal of Clinical Oncology, 43(16_suppl):TPS2677-TPS2677.","DOI":"10.1200\/JCO.2025.43.16_suppl.TPS2677"},{"key":"10317_CR142","doi-asserted-by":"crossref","unstructured":"Punekar, S.R., et al., (2025)\u00a0EVEREST-2: Initial data of the logic-gated Tmod chimeric antigen receptor T-cell (CAR T) therapy A2B694 for patients with solid tumors associated with mesothelin (MSLN) expression and with human leukocyte antigen (HLA) loss of heterozygosity (LOH). Journal of Clinical Oncology, 43(16_suppl):3040\u20133040.","DOI":"10.1200\/JCO.2025.43.16_suppl.3040"},{"key":"10317_CR143","doi-asserted-by":"crossref","unstructured":"Venkataraman, S., et al., (2024) Developing a safe and potent tumor-targeting gated CAR-T cell therapy for DIPG: A deadly pediatric brain tumor. Cancer Research, 84(17):PR010.","DOI":"10.1158\/1538-7445.PEDIATRIC24-PR010"},{"key":"10317_CR144","doi-asserted-by":"publisher","DOI":"10.1093\/neuonc\/noad179.0987","volume":"25","author":"H Soderholm","year":"2023","unstructured":"Soderholm, H., et al. (2023). Combining flash radiotherapy with GD2-CAR T cell immunotherapy in diffuse intrinsic pontine glioma. Neuro-Oncology, 25, Article v257.","journal-title":"Neuro-Oncology"},{"key":"10317_CR145","first-page":"A364","volume":"12","author":"IH Ansari","year":"2024","unstructured":"Ansari, I. H., et al. (2024). Improving pediatric neuroblastoma immunotherapy outcome by using B7\u2013H3 CAR-T cells in combination with low-dose external beam radiation therapy (EBRT): Preclinical development in murine models. Journal for ImmunoTherapy of Cancer, 12, A364.","journal-title":"Journal for ImmunoTherapy of Cancer"},{"key":"10317_CR146","doi-asserted-by":"crossref","unstructured":"Barisa, M., et al., (2025)\u00a0Functional avidity of anti-B7H3 CAR-T constructs predicts antigen density thresholds for triggering effector function. Nature Communications, 16(1):7196.","DOI":"10.1038\/s41467-025-61427-4"},{"key":"10317_CR147","doi-asserted-by":"crossref","unstructured":"De Mitri, F., et al., (2025) Inhibition of autophagy enhances the antitumor efficacy of T\/CAR T cell against neuroblastoma. Journal of Experimental and Clinical Cancer Research, 44(1):185.","DOI":"10.1186\/s13046-025-03492-7"},{"key":"10317_CR148","doi-asserted-by":"publisher","DOI":"10.1016\/j.phrs.2025.107608","author":"L Grunewald","year":"2025","unstructured":"Grunewald, L., et al. (2025). Targeting MYCN upregulates L1CAM tumor antigen in MYCN-dysregulated neuroblastoma to increase CAR T cell efficacy. Pharmacological Research. https:\/\/doi.org\/10.1016\/j.phrs.2025.107608","journal-title":"Pharmacological Research"},{"key":"10317_CR149","doi-asserted-by":"crossref","unstructured":"Launspach, M., et al. (2025). Personalized CRISPR knock-in cytokine gene therapy to remodel the tumor microenvironment and enhance CAR T cell therapy in solid tumors.\u00a0Nature Communications, 16(1), 10987.","DOI":"10.1038\/s41467-025-67328-w"},{"key":"10317_CR150","doi-asserted-by":"publisher","DOI":"10.1016\/j.iotech.2024.100863","volume":"24","author":"F Rossari","year":"2024","unstructured":"Rossari, F., et al. (2024). 52P tumor-targeted cytokine release by genetically-engineered myeloid cells rescues CAR-T activity and engages endogenous T cells against high-grade glioma in mouse models. Immuno-Oncology and Technology, 24, Article 100863.","journal-title":"Immuno-Oncology and Technology"},{"key":"10317_CR151","doi-asserted-by":"crossref","unstructured":"Tian, M., et al., (2022) An optimized bicistronic chimeric antigen receptor against GPC2 or CD276 overcomes heterogeneous expression in neuroblastoma. Journal of Clinical Investigation,\u00a0132(16):e15562.","DOI":"10.1172\/JCI155621"},{"issue":"11","key":"10317_CR152","doi-asserted-by":"publisher","first-page":"1308","DOI":"10.1016\/j.jcyt.2024.05.023","volume":"26","author":"H Wu","year":"2024","unstructured":"Wu, H., et al. (2024). Enhanced anti-tumor activity mediated by combination chimeric antigen receptor T cells targeting GD2 and GPC2 in high-risk neuroblastoma. Cytotherapy, 26(11), 1308\u20131319.","journal-title":"Cytotherapy"},{"key":"10317_CR153","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2025.115263","volume":"218","author":"JGM Strijker","year":"2025","unstructured":"Strijker, J. G. M., et al. (2025). Blocking MIF secretion enhances CAR T-cell efficacy against neuroblastoma. European Journal of Cancer, 218, Article 115263.","journal-title":"European Journal of Cancer"},{"issue":"3","key":"10317_CR154","doi-asserted-by":"publisher","first-page":"1212","DOI":"10.7150\/thno.92481","volume":"14","author":"NF Trautwein","year":"2024","unstructured":"Trautwein, N. F., et al. (2024). A novel approach to guide GD2-targeted therapy in pediatric tumors by PET and [64Cu]Cu-NOTAch14.18\/ CHO. Theranostics, 14(3), 1212\u20131223.","journal-title":"Theranostics"},{"key":"10317_CR155","unstructured":"Ghosh, A., et al., (2024) [89Zr]p-SCN-Bz-DFO-B7-H3: A novel PET tracer to guide B7-H3 CAR-T cell therapy for solid tumors. Journal of Nuclear Medicine, 65:241457."},{"issue":"1","key":"10317_CR156","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1016\/j.ccell.2023.11.011","volume":"42","author":"S Kaczanowska","year":"2024","unstructured":"Kaczanowska, S., et al. (2024). Immune determinants of CAR-T cell expansion in solid tumor patients receiving GD2 CAR-T cell therapy. Cancer Cell, 42(1), 35-51.e8.","journal-title":"Cancer Cell"},{"issue":"8_Supplement_1","key":"10317_CR157","doi-asserted-by":"publisher","first-page":"7123","DOI":"10.1158\/1538-7445.AM2025-7123","volume":"85","author":"Y Chen","year":"2025","unstructured":"Chen, Y., et al. (2025). Abstract 7123: Unravelling temporal dynamics of GD2-CAR T cell therapy in H3K27M-mutant diffuse midline glioma through comprehensive single-cell and multi-omic profiling. Cancer Research, 85(8_Supplement_1), 7123\u20137123.","journal-title":"Cancer Research"},{"issue":"16_suppl","key":"10317_CR158","doi-asserted-by":"publisher","first-page":"e19085","DOI":"10.1200\/JCO.2025.43.16_suppl.e19085","volume":"43","author":"Z Fatima","year":"2025","unstructured":"Fatima, Z., et al. (2025). Evaluating peripheral eosinophilia as a biomarker post CAR-T cell therapy. Journal of Clinical Oncology, 43(16_suppl), e19085\u2013e19085.","journal-title":"Journal of Clinical Oncology"},{"issue":"16_suppl","key":"10317_CR159","first-page":"e15182","volume":"43","author":"G Li","year":"2025","unstructured":"Li, G., et al. (2025). Delivery of B7H3-targeted CAR-T cells in injectable silk hydrogels and effects on the efficacy in treating solid tumors. Journal of Clinical Oncology, 43(16_suppl), e15182\u2013e15182.","journal-title":"Journal of Clinical Oncology"},{"key":"10317_CR160","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2022-005583","author":"X Dong","year":"2023","unstructured":"Dong, X., et al. (2023). Anti-VEGF therapy improves EGFR-vIII-CAR-T cell delivery and efficacy in syngeneic glioblastoma models in mice. Journal for ImmunoTherapy of Cancer. https:\/\/doi.org\/10.1136\/jitc-2022-005583","journal-title":"Journal for ImmunoTherapy of Cancer"},{"issue":"8","key":"10317_CR161","doi-asserted-by":"publisher","first-page":"11937","DOI":"10.1021\/acsami.5c00633","volume":"17","author":"J Parra-Nieto","year":"2025","unstructured":"Parra-Nieto, J., et al. (2025). Liposomal-based nanoarchitectonics as bispecific T cell engagers in neuroblastoma therapy. ACS Applied Materials & Interfaces, 17(8), 11937\u201311945.","journal-title":"ACS Applied Materials & Interfaces"},{"issue":"16_suppl","key":"10317_CR162","doi-asserted-by":"publisher","first-page":"TPS11581","DOI":"10.1200\/JCO.2023.41.16_suppl.TPS11581","volume":"41","author":"CM Albert","year":"2023","unstructured":"Albert, C. M., et al. (2023). ENLIGHten-01: A phase 1 study of fluorescein-specific (FITC-E2)-CAR T cells in combination with folate-fluorescein (UB-TT170) for osteosarcoma. Journal of Clinical Oncology, 41(16_suppl), TPS11581\u2013TPS11581.","journal-title":"Journal of Clinical Oncology"},{"issue":"4","key":"10317_CR163","doi-asserted-by":"publisher","first-page":"1445","DOI":"10.1007\/s10555-024-10214-6","volume":"43","author":"T Trautmann","year":"2024","unstructured":"Trautmann, T., Yakobian, N., & Nguyen, R. (2024). CAR T-cells for pediatric solid tumors: Where to go from here? Cancer Metastasis Reviews, 43(4), 1445\u20131461.","journal-title":"Cancer Metastasis Reviews"},{"issue":"8_Supplement_1","key":"10317_CR164","doi-asserted-by":"publisher","first-page":"1372","DOI":"10.1158\/1538-7445.AM2025-1372","volume":"85","author":"JT Plummer","year":"2025","unstructured":"Plummer, J. T., et al. (2025). Abstract 1372: Development of a multi-omic spatial phenotyping assay for affirmative detection of CAR-T cells in the tumor immune microenvironment of solid pediatric tumors. Cancer Research, 85(8_Supplement_1), 1372\u20131372.","journal-title":"Cancer Research"},{"issue":"4","key":"10317_CR165","doi-asserted-by":"publisher","first-page":"208","DOI":"10.14791\/btrt.2024.0037","volume":"12","author":"A Ju","year":"2024","unstructured":"Ju, A., et al. (2024). Lymphodepletion in chimeric antigen receptor T-cell therapy for solid tumors: A focus on brain tumors. Brain Tumor Research and Treatment, 12(4), 208\u2013220.","journal-title":"Brain Tumor Research and Treatment"}],"container-title":["Cancer and Metastasis Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10555-026-10317-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10555-026-10317-2","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10555-026-10317-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,2]],"date-time":"2026-03-02T18:02:23Z","timestamp":1772474543000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10555-026-10317-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,2]]},"references-count":165,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,3]]}},"alternative-id":["10317"],"URL":"https:\/\/doi.org\/10.1007\/s10555-026-10317-2","relation":{},"ISSN":["1573-7233"],"issn-type":[{"value":"1573-7233","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3,2]]},"assertion":[{"value":"2 October 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 February 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 March 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"No ethical approval or informed consent was needed because the article did not involve human or animal subjects.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"No human participants were involved in this review article.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"No IRB approval was obtained as this article did not involve human subjects or associated data.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"IRB approval"}},{"value":"Not applicable.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Clinical trial number"}},{"value":"The authors declare no competing interests.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"10"}}